Is Walgreens Stock a Buy?

Walgreens Boots Alliance's financial performance has been weak, reporting a GAAP loss in Q1 2025 and adjusted earnings significantly below the prior year, leading to a dividend reduction and suspension. The company agreed to be acquired by Sycamore Partners for $11.45 per share, offering a small arbitrage opportunity; however, a potential additional $3 per share payout tied to its health clinic investment is highly uncertain, making the stock unattractive for most investors.

Analysis

Walgreens Boots Alliance (WBA) is grappling with significant operational and financial challenges, as evidenced by its recent performance and strategic shifts. The company reported a GAAP loss in the first quarter of 2025, and its adjusted earnings per share plummeted to $0.63 from $1.20 in the prior year, reflecting severe underlying business weakness. This downturn is attributed to a saturated U.S. pharmacy market, intensified competition from diverse retail channels including grocery stores and online platforms, and strategic missteps such as a costly foray into operating health clinics, which resulted in a $4.2 billion impairment charge. Consequently, WBA drastically reduced its dividend in early 2024 and suspended it entirely by early 2025, signaling deep financial distress. The company has agreed to an acquisition by Sycamore Partners at $11.45 per share. With the stock trading around $11.20, this presents a marginal arbitrage opportunity of approximately 2%, or $0.25 per share. An additional contingent payment of $3 per share, dependent on extracting value from its health clinic investments, is highly speculative with no firm timeline, rendering it a gamble. The impending privatization means any potential turnaround benefits will not accrue to current public shareholders beyond the acquisition terms.

Key Decisions for Investors

• Consider WBA primarily as a special situation arbitrage play, with a current potential return of approximately 2% if the Sycamore Partners acquisition at $11.45 per share completes as planned, given the stock price is around $11.20.
• Acknowledge the substantial downside risk should the acquisition fail, as WBA's standalone fundamentals are weak, highlighted by a Q1 2025 GAAP loss, significantly lower adjusted earnings, and a suspended dividend.
• Treat the potential additional $3 per share payout from the health clinic assets as highly speculative and uncertain, and avoid factoring it heavily into any investment decision due to the lack of guarantees or a clear timeline.
• For investors not focused on merger arbitrage, WBA likely represents an unattractive investment due to the limited upside defined by the buyout offer and the considerable risk associated with the company's distressed financial state and uncertain contingent payments.